Narrow search
Showing 1 - 10 of 592
Cover Image
Firms, Failures, and Fluctuations : The Macroeconomics of Supply Chain Disruptions
Acemoglu, Daron - 2020
This paper studies how firm failures and the resulting disruptions to supply chains can amplify negative shocks. We develop a non-competitive model where customized supplier-customer relations increase productivity, and the relationship-specific surplus generated between firms and their...
Persistent link: https://www.econbiz.de/10012481420
Cover Image
Labor Dynamics and Supply Chain Disruption in Food Manufacturing
Ramsey, A. Ford; Goodwin, Barry K.; Haley, Mildred A. - National Bureau of Economic Research - 2021
Food manufacturing and processing is an important link between agricultural producers and consumers in the agricultural … supply chain. The food manufacturing sector in the United States is both increasingly mechanized and increasingly … concentrated. Consequently, labor risks in food manufacturing have changed over time with changes in industry structure. Labor …
Persistent link: https://www.econbiz.de/10012585380
Cover Image
Exchange Rate Volatility and Global Food Supply Chains
Steinbach, Sandro - National Bureau of Economic Research - 2021
This paper analyzes the impact of exchange rate risk on global food supply chains. Although the theoretical literature … for a balanced panel of 159 countries for 2001 to 2017. I study the relationship for 781 agricultural and food products … a primary source of international risk exposure for global food supply chains …
Persistent link: https://www.econbiz.de/10012616612
Cover Image
Do Pharmacists Buy Bayer? Informed Shoppers and the Brand Premium
Bronnenberg, Bart J. - 2014
similar non-chefs. We extend our analysis to cover 50 retail health categories and 241 food and drink categories. The results …, and a much smaller share for most food and drink products. We tie our estimates together using a stylized model of demand …
Persistent link: https://www.econbiz.de/10012458372
Cover Image
Risks and global supply chains : What we know and what we need to know
Baldwin, Richard E.; Freeman, Rebecca - National Bureau of Economic Research - 2021
Recent supply disruptions catapulted the issue of risk in global supply chains (GSCs) to the top of policy agendas and created the impression that shortages would have been less severe if GSCs were either shorter and more domestic, or more diversified. But is this right? We start our answer by...
Persistent link: https://www.econbiz.de/10012660121
Cover Image
Supply Chain Risk : Changes in Supplier Composition and Vertical Integration
Ersahin, Nuri; Giannetti, Mariassunta; Huang, Ruidi - National Bureau of Economic Research - 2023
Using textual analysis of earnings conference calls, we quantify firms' supply chain risk and its sources. Our proxy for supply chain risk exhibits large cross-sectional and time-series variation that aligns with reasonable priors and is unprecedently high during the Covid-19 pandemic. In...
Persistent link: https://www.econbiz.de/10014250152
Cover Image
Supply Chain Resilience : Evidence from Indian Firms
Khanna, Gaurav; Morales, Nicolas; Pandalai-Nayar, Nitya - National Bureau of Economic Research - 2022
We characterize what features make supply chains more resilient. Using new data on the universe of firm-to-firm transactions from an Indian state, we identify firms with larger supplier risk following the Covid-19 lockdowns. Using an event-study design we find firms with suppliers in...
Persistent link: https://www.econbiz.de/10013462737
Cover Image
Consumption Externalities and Diffusion in Pharmaceutical Markets : Antiulcer Drugs
Berndt, Ernst R. - 2000
We examine the role of consumption externalities in the demand for pharmaceuticals at both the brand level and over a …
Persistent link: https://www.econbiz.de/10012470978
Cover Image
Network Effects and Diffusion in Pharmaceutical Markets : Antiulcer Drugs
Berndt, Ernst R. - 1999
We examine the role of network effects in the demand for pharmaceuticals at both the brand level and for a therapeutic …
Persistent link: https://www.econbiz.de/10012471776
Cover Image
No Free Launch : At-Risk Entry by Generic Drug Firms
Drake, Keith M.; He, Robert; McGuire, Thomas G.; … - National Bureau of Economic Research - 2021
After receiving FDA approval, a generic drug manufacturer can launch "at risk" before conclusion of any patent infringement litigation, but it risks paying damages if it loses. The generic can eliminate the risk by waiting to launch until the appeals process is complete but waiting has downsides...
Persistent link: https://www.econbiz.de/10012616579